Plasmodium vivax, a Human Malaria Parasite Resilient to Elimination
Why is it so difficult to eliminate the "forgotten" malaria parasite Plasmodium vivax? The PvREX research group at ISGlobal and IGTP presents recent scientific data.
At the IGTP TODAY
Why is it so difficult to eliminate the "forgotten" malaria parasite Plasmodium vivax? The PvREX research group at ISGlobal and IGTP presents recent scientific data.
According to a study led by CEEISCAT-IGTP and conducted with the PISCIS cohort, individuals with HIV who have had COVID-19 face a 30% higher risk of developing cardiovascular diseases.
The results of a pioneering study by IGTP and BST support the safety of the bioimplants called PeriCord, made from stem cells of the umbilical cord and pericardium from a tissue donor, which aid in the regeneration and revascularisation of the affected area.
A study led by researchers from IGTP, in collaboration with health economics experts from Can Ruti, UPF, and Agència de Salut Pública de Barcelona, offers new recommendations for optimising tuberculosis screening programmes in low-incidence countries. Published in the journal Eurosurveillance, this work reviews various studies to determine if these programmes targeting higher-risk groups are economically effective.
IGTP’s Biostatistics Unit have recently published two notable articles. The first paper, appearing in Scientific Reports, reveals the role of socioeconomic inequalities and vaccination in the spread of the pandemic. The second, published in BMC Medical Research Methodology, introduces REDCapDM, a new R package designed to enhance efficiency and reliability in the management of research data collected through the popular REDCap platform.
On 21 March, the final meeting of INNOVA4TB, a consortium led by IGTP with researchers from around the world, took place. Participants presented the results of the different work packages and evaluated the work done since 2019. IGTP will continue to be involved in other networks such as ADVANCE-TB and SMA-TB.
Researchers from IGTP and Ahead Therapeutics have been exploring a treatment based on liposome-type nanoparticles to address the autoimmunity of type 1 diabetes for years. A study recently published in the Journal of Autoimmunity examines the response of macrophages to this immunotherapy, serving as a preliminary step before clinical trials.
Researchers from IGTP and BSC-CNS have discovered new genetic mechanisms related to spinocerebellar ataxia type 37. Their research, published in the journal Human Genetics, employed advanced techniques such as CRISPR/Cas9 gene editing, real-time large DNA sequencing and machine learning. The study deepens our understanding of this inherited disease, leading to more precise diagnoses and improved genetic counselling for patients.
Researchers from IGTP have made progress exploring potential treatments for skin tumours associated with neurofibromatosis type 1. Their findings in cell models have been published in the journal JCI Insight.
An international team of researchers identifies the genetic basis and biological processes that influence cancer risk related to alterations in the number of immune cells present in blood. This is a significant advance in the understanding of how the immune system can prevent the appearance of tumours.